摘要
目的 :对转移性非小细胞肺癌患者应用ZD1839后的疗效及不良事件进行观察。方法 :选择 4 3例NSCLC病人 ,给予ZD1839治疗 ,90天后对其疗效及不良反应进行观察统计。结果 :4 3例服用ZD1839的病人中 ,90天后CR率 2 3% ,PR率 16 3% ,SD率 32 6 % ,疾病控制率 (CR +PR +SD) 5 1 2 % ;不良事件观察 :皮疹 4 8 8% ,腹泻 2 7 9% ,转氨酶升高11 6 % ,恶心、呕吐 14 0 % ,未观察到间质性肺炎病例。结论 :从疾病控制和毒副反应结果分析 ,ZD1839是一类可以用于临床的抗肿瘤新药 。
Objective:To observe the curative effect and adverse event of non-small cell lung cancer(NSCLC) patients who took ZD1839.Methods:We chose 43 patients who took ZD1839 and invested the curative effect and adverse event after 90 days.Results:In the 43 patients,CR,PR,SD rate were 2.3%,16.3%,32.6% respectively.Disease control rate was 51.2%.Adverse events:rash,diarrhea,step-up of aminotransferase,nausea and vomiting were reported by 48.8%,27.9%,11.6% and 14.0% respectively.No interstitial lung disease was found.Conclusion:We confirm ZD1839 is a new drug which can be adapted to tumor patients according to its disease control rates and adverse events.It shows good prospect to patient which suffer from advanced and metastatic tumor.
出处
《临床肿瘤学杂志》
CAS
2004年第6期581-585,共5页
Chinese Clinical Oncology